Company intelligence / Profile preview

MGI GP

Baltimore, Maryland, USA

Ownership: Private
Development stage: Other

Overview

MGI GP, Inc., formerly known as Guilford Pharmaceuticals, is a biopharmaceutical company that became a subsidiary of MGI Pharma following its acquisition in 2005. Based in Baltimore, Maryland, the company specialized in the development and commercialization of therapeutics for oncology and acute care, most notably the Gliadel Wafer for brain cancer and Aggrastat for cardiovascular conditions. Following the subsequent acquisition of MGI Pharma by Eisai Co., Ltd. in 2008, MGI GP's operations and assets were integrated into Eisai's global portfolio. The company's research legacy includes pioneering work in PARP inhibition and biodegradable polymer drug delivery systems.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Baxter Healthcare

Beyond the preview

Go deeper on MGI GP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGI GP.

Explore the full profile